Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
AbbVie Sues HHS Over Medicare Price Controls on Botox Under Inflation Reduction Act 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Instagram CEO Defends Platform in Youth Mental Health Lawsuit Over Social Media Addiction Claims 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Lyft Shares Slide After Weak Q1 Profit Forecast and Surprise 2025 Operating Loss 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
How Marco Pharma International Preserves German Homeopathic Traditions in America 
FAA Confirms $1.5 Billion Peraton Contract as U.S. Air Traffic Control Overhaul Accelerates 
Boeing Reports Major Supply Chain Quality Improvements After Spirit AeroSystems Deal 
Standard Chartered Names Peter Burrill as Interim Group CFO Following Diego De Giorgi’s Exit 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
xAI Co-Founder Jimmy Ba Departs as Elon Musk’s AI Startup Faces Turbulence 
EMERYVILLE, Calif., April 11, 2018 -- Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of rare central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, Gail Farfel, Ph.D., Executive Vice President and Chief Development Officer, and Michael P. Smith, Executive Vice President, Chief Financial Officer, Treasurer and Secretary, will provide a corporate update at the LEERINK Partners CNS Day, being held in New York City on April 18, 2018.
LEERINK Partners CNS Day – Zogenix Presentation Details
Date: Wednesday, April 18, 2018
Time: 2:40 pm Eastern Time / 11:40 am Pacific Time
Location: New York, NY - Convene Conference Center
The presentation will be webcast live and archived for 90 days on Zogenix's Investor Relations website at www.ir.zogenix.com.
About Zogenix
Zogenix, Inc. (NASDAQ:ZGNX) is a pharmaceutical company committed to developing and commercializing CNS therapies that address specific clinical needs for people living with orphan and other CNS disorders who need innovative treatment alternatives to improve their daily functioning.
For more information, visit www.zogenix.com.
CONTACT:
Investors:
Andrew McDonald
Founding Partner, LifeSci Advisors LLC
646-597-6987
[email protected]
